Yuehui Zhao

Nov 6, 2024 | digitalcommons.library.tmc.edu | Wei Shi |Yin Wang |Yuehui Zhao |Justin Kim

Checkpoint immunotherapy has yielded meaningful responses across many cancers but has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7-H3/CD276) is an immune checkpoint molecule and has emerged as a promising therapeutic target. However, much remains to be understood regarding B7-H3's role in cancer progression, predictive biomarkers for B7-H3-targeted therapy, and combinatorial strategies.